RECURSION PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.46M, a 47.20% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $2.79M, a 33.52% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $2.71M, a 32.88% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $732.00K, a 75.56% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $4.09M, a 50.77% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $8.30M, a 35.32% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $12.83M, a 21.07% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $10.60M, a 55.58% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $4.09M 10-K · filed 2026-02-25 | |
| 2025-06-30 | $1.46M 10-Q · filed 2025-08-05 | $7.69M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $2.79M 10-Q · filed 2025-05-05 | $9.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.30M 10-K · filed 2026-02-25 |
| 2024-09-30 | $732.00K 10-Q · filed 2024-11-06 | $9.63M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $2.77M 10-Q · filed 2025-08-05 | $11.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $2.09M 10-Q · filed 2025-05-05 | $14.04M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.83M 10-K · filed 2026-02-25 |
| 2023-09-30 | $3.00M 10-Q · filed 2024-11-06 | $12.65M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $4.91M 10-Q · filed 2024-08-08 | $11.45M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $882.00K 10-Q · filed 2024-05-09 | $10.32M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $10.60M 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.79M 10-Q · filed 2023-11-09 | $10.19M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.79M 10-Q · filed 2023-08-08 | $8.78M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.16M 10-Q · filed 2023-05-08 | $5.82M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.81M 10-K · filed 2024-02-29 |
| 2021-09-30 | $382.00K 10-Q · filed 2022-11-08 | $3.81M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $823.00K 10-Q · filed 2022-08-09 | $3.64M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.15M 10-Q · filed 2022-05-10 | $2.82M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $681.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $211.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | |
| 2020-03-31 | $16.00K 10-Q · filed 2021-05-12 | |
| 2019-12-31 | $65.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |